Brief: Serina Therapeutics Announces FDA Clearance Of Ind Application For Ser-252 For The Treatment Of Advanced Parkinson’S Disease
28/01/2026 21:20
Jan 28 (Reuters) - Serina Therapeutics Inc SER.A: SERINA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR SER-252 FOR THE TREATMENT OF ADVANCED PARKINSON’S DISEASE Source text: ID:nGNX2FKs2f Further company coverage: SER.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Serina Therapeutics
See all newsBrief: Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2
Brief: Serina Therapeutics - Offers Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments - SEC Filing
Serina Therapeutics Q2 net loss widens on higher expenses
Brief: Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors
Brief: Serina Therapeutics Completes Sentinel Dosing In Cohort 1 Of Phase 1B Registrational Trial Of SER-252